REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO (Nasdaq: RGNX) has announced its participation in three major healthcare investor conferences in late 2024.

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) has announced its participation in three major healthcare investor conferences in late 2024. The company will present at the UBS Global Healthcare Conference on November 13 in Rancho Palos Verdes, the Stifel Healthcare Conference on November 19 in New York, and the Piper Sandler Annual Healthcare Conference on December 5 in New York. All presentations will be available via live webcast through REGENXBIO's website, with recordings accessible for approximately 30 days after each event.

Argus Session date unavailable

-0.34% session move Open Argus

Details

News Market Reaction – RGNX

The recorded move for RGNX in the trading session of this news was -0.34%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

UBS Global Healthcare Conference 
Fireside Chat: Wednesday, November 13 at 12:30 p.m. PT
Location: Rancho Palos Verdes, CA

Stifel 2024 Healthcare Conference 
Fireside Chat: Tuesday, November 19 at 11:30 a.m. ET
Location: New York, NY

Piper Sandler 36th Annual Healthcare Conference 
Fireside Chat: Thursday, December 5 at 9:30 a.m. ET
Location: New York, NY

Live webcasts of the fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma^® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302294648.html

SOURCE REGENXBIO Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is REGENXBIO (RGNX) presenting at the UBS Global Healthcare Conference 2024?

REGENXBIO will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 12:30 p.m. PT in Rancho Palos Verdes, CA.

How can I watch REGENXBIO's (RGNX) investor conference presentations in November-December 2024?

Live webcasts of REGENXBIO's presentations can be accessed through the Investors section of their website at www.regenxbio.com, with replays available for approximately 30 days after each presentation.

Which investor conferences is REGENXBIO (RGNX) attending in late 2024?

REGENXBIO is participating in three conferences: the UBS Global Healthcare Conference (November 13), the Stifel Healthcare Conference (November 19), and the Piper Sandler Healthcare Conference (December 5).